A Novel Nomogram for the Preoperative Prediction of Edmondson-Steiner Grade III-IV in Hepatocellular Carcinoma Patients

References

• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(5):541–565. doi:10.6004/jnccn.2021.0022
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Zhou L, Rui JA, Wang SB, et al. Prognostic factors of solitary large hepatocellular carcinoma: the importance of differentiation grade. Eur J Surg Oncol. 2011;37(6):521–525. doi:10.1016/j.ejso.2011.03.137
   PubMed Web of Science ®Google Scholar
• Zeng J, Zeng J, Lin K, et al. Development of a machine learning model to predict early recurrence for hepatocellular carcinoma after curative resection. Hepatobiliary Surg Nutr. 2022;11(2):176–187. doi:10.21037/hbsn-20-466
   PubMedGoogle Scholar
• Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462–503. doi:10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e
   PubMed Web of Science ®Google Scholar
• Kim SU, Jung KS, Lee S, et al. Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. Liver Int. 2014;34(7):1008–1017. doi:10.1111/liv.12475
   PubMed Web of Science ®Google Scholar
• Zhu P, Liao W, Zhang WG, et al. A prospective study using propensity score matching to compare long-term survival outcomes after robotic-assisted, laparoscopic, or open liver resection for patients with BCLC stage 0-A Hepatocellular carcinoma. Ann Surg. 2023;277(1):e103–e111. doi:10.1097/SLA.0000000000005380
   PubMed Web of Science ®Google Scholar
• Xu LX, He MH, Dai ZH, et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann Oncol. 2019;30(6):990–997. doi:10.1093/annonc/mdz103
   PubMed Web of Science ®Google Scholar
• Chang YS, Chou YP, Chung CC, et al. Molecular classification of Hepatocellular carcinoma using wnt-hippo signaling pathway-related genes. Cancers. 2022;14(19):4580. doi:10.3390/cancers14194580
   PubMed Web of Science ®Google Scholar
• Mou H, Yang QA, Yu L, et al. Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics. J Gastroenterol Hepatol. 2021;36(9):2601–2609. doi:10.1111/jgh.15475
   PubMed Web of Science ®Google Scholar
• Qu C, Huang X, Liu K, et al. Effect of hepatitis B virus DNA replication level and anti-HBV therapy on microvascular invasion of hepatocellular carcinoma. Infect Agent Cancer. 2019;14:2. doi:10.1186/s13027-019-0219-8
   PubMed Web of Science ®Google Scholar
• Yang P, Si A, Yang J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion. Surgery. 2019;165(4):721–730. doi:10.1016/j.surg.2018.09.016
   PubMed Web of Science ®Google Scholar
• Jiao S, Li G, Zhang D, et al. Anatomic versus non-anatomic resection for hepatocellular carcinoma, do we have an answer? A meta-analysis. Int J Surg. 2020;80:243–255. doi:10.1016/j.ijsu.2020.05.008
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of Hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682–720. doi:10.1159/000509424
   PubMed Web of Science ®Google Scholar
• Wang L, Ke Q, Lin K, et al. Not all Hepatocellular carcinoma patients with microvascular invasion after R0 resection could be benefited from prophylactic transarterial chemoembolization: a propensity score matching study. Cancer Manag Res. 2020;12:3815–3825. doi:10.2147/CMAR.S251605
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.9791
   PubMed Web of Science ®Google Scholar
• Tang M, Zhou Q, Huang M, et al. Nomogram development and validation to predict hepatocellular carcinoma tumor behavior by preoperative gadoxetic acid-enhanced MRI. Eur Radiol. 2021;31(11):8615–8627. doi:10.1007/s00330-021-07941-7
   PubMed Web of Science ®Google Scholar
• Mao Y, Wang J, Zhu Y, et al. Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2022;11(1):13–24. doi:10.21037/hbsn-19-870
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Mao S, Yu X, Shan Y, et al. Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-based nomogram model to predict tumor recurrence of AFP-negative hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1355–1365. doi:10.2147/JHC.S339707
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang HL, Liu QP, et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol. 2019;70(6):1133–1144. doi:10.1016/j.jhep.2019.02.023
   PubMed Web of Science ®Google Scholar
• Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage Hepatocellular carcinoma: a multi-institutional study. Radiology. 2020;294(3):568–579. doi:10.1148/radiol.2020191470
   PubMed Web of Science ®Google Scholar
• Tayob N, Kanwal F, Alsarraj A, et al. The performance of AFP, AFP-3, DCP as biomarkers for detection of Hepatocellular carcinoma (HCC): a Phase 3 biomarker study in the United States. Clin Gastroenterol Hepatol. 2023;21(2):415–423.e4. doi:10.1016/j.cgh.2022.01.047
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Lei Z, Li J, Wu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria. JAMA Surg. 2016;151(4):356–363. doi:10.1001/jamasurg.2015.4257
   PubMed Web of Science ®Google Scholar
• Wang MD, Sun LY, Qian GJ, et al. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: a retrospective cohort study. Int J Surg. 2022;105:106843. doi:10.1016/j.ijsu.2022.106843
   PubMed Web of Science ®Google Scholar
• Zhou Z, Liu J, Xu X. A commentary on ‘Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: a retrospective cohort study’. Int J Surg. 2023;105:106843. doi:10.1097/JS9.0000000000000119
   Web of Science ®Google Scholar
• He YZ, He K, Huang RQ, et al. Preoperative evaluation and prediction of clinical scores for hepatocellular carcinoma microvascular invasion: a single-center retrospective analysis. Ann Hepatol. 2020;19(6):654–661. doi:10.1016/j.aohep.2020.07.002
   PubMed Web of Science ®Google Scholar
• Wei X, Li N, Li S, et al. Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma. BMC Cancer. 2017;17(1):304. doi:10.1186/s12885-017-3293-6
   PubMed Web of Science ®Google Scholar
• Yoo S, Kim JY, Lim YS, et al. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. J Hepatol. 2022;77(4):939–946. doi:10.1016/j.jhep.2022.05.014
   PubMed Web of Science ®Google Scholar
• Hoshida Y. Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence. J Hepatol. 2009;51(5):842–844. doi:10.1016/j.jhep.2009.08.003
   PubMed Web of Science ®Google Scholar
• Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890–897. doi:10.1016/j.jhep.2009.07.009
   PubMed Web of Science ®Google Scholar
• Li Z, Lei Z, Xia Y, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related Hepatocellular carcinoma. JAMA Surg. 2018;153(10):e182721. doi:10.1001/jamasurg.2018.2721
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhangyuan G, Wang F, et al. The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. Immunity. 2021;54(6):1168–1185.e8. doi:10.1016/j.immuni.2021.04.027
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Foschi FG, Conti F, et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Dig Liver Dis. 2019;51(5):681–688. doi:10.1016/j.dld.2018.09.016
   PubMedGoogle Scholar
• Liao M, Sun J, Zhang Q, et al. A novel post-operative ALRI model accurately predicts clinical outcomes of resected Hepatocellular carcinoma patients. Front Oncol. 2021;11:665497. doi:10.3389/fonc.2021.665497
   PubMed Web of Science ®Google Scholar
• Li P, Huang W, Wang F, et al. Nomograms based on inflammatory biomarkers for predicting tumor grade and micro-vascular invasion in stage I/II hepatocellular carcinoma. Biosci Rep. 2018;38(6):BSR20180464. doi:10.1042/BSR20180464
   PubMed Web of Science ®Google Scholar
• Krishnan MS, Rajan Kd A, Park J, et al. Genomic analysis of vascular invasion in HCC reveals molecular drivers and predictive biomarkers. Hepatology. 2021;73(6):2342–2360. doi:10.1002/hep.31614
   PubMed Web of Science ®Google Scholar
• Costentin CE, Ferrone CR, Arellano RS, et al. Hepatocellular carcinoma with macrovascular invasion: defining the optimal treatment strategy. Liver Cancer. 2017;6(4):360–374. doi:10.1159/000481315
   PubMed Web of Science ®Google Scholar
• Chekmarev J, Azad MG, Richardson DR. The oncogenic signaling disruptor, NDRG1: molecular and cellular mechanisms of activity. Cells. 2021;10(9):2382. doi:10.3390/cells10092382
   PubMed Web of Science ®Google Scholar
• Chua MS, Sun H, Cheung ST, et al. Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol. 2007;20(1):76–83. doi:10.1038/modpathol.3800711
   PubMed Web of Science ®Google Scholar